Correction: Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.

IF 4.7 2区医学 Q1 RHEUMATOLOGY RMD Open Pub Date : 2025-01-27 DOI:10.1136/rmdopen-2024-004865corr1

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

修正：盐酸jaktinib片治疗活动性轴型脊柱炎的疗效和安全性：一项多中心、随机、双盲、安慰剂对照的II期临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

RMD Open RHEUMATOLOGY-

CiteScore

7.30

自引率

6.50%

发文量

205

审稿时长

14 weeks

期刊介绍： RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

期刊最新文献

Can alternative means of phenotyping rheumatoid arthritis reduce its apparent heterogeneity? A comparison of three disease activity classifications with DAS28. Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort. Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spondyloarthritis. Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection. Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network.